title: The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
abstract: We retrospectively evaluated the accumulation of fluorodeoxy glucose (FDG) in pulmonary malignancies without local recurrence during 2-year follow-up on positron emission tomography (PET)/computed tomography (CT) after radiofrequency ablation (RFA). Thirty tumors in 25 patients were studied (10 non-small cell lung cancers;20 pulmonary metastatic tumors). PET/CT was performed before RFA, 3 months after RFA, and 6 months after RFA. We assessed the FDG accumulation with the maximum standardized uptake value (SUVmax) compared with the diameters of the lesions. The SUVmax had a decreasing tendency in the first 6 months and, at 6 months post-ablation, FDG accumulation was less affected by inflammatory changes than at 3 months post-RFA. The diameter of the ablated lesion exceeded that of the initial tumor at 3 months post-RFA and shrank to pre-ablation dimensions by 6 months post-RFA. SUVmax was more reliable than the size measurements by CT in the first 6 months after RFA, and PET/CT at 6 months post-RFA may be more appropriate for the assessment of FDG accumulation than that at 3 months post-RFA.
authors.affiliation: Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. arafat920@hotmail.com
authors.forename: Aierken
authors.initials: A
authors.lastname: Alafate
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Shinya
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Okumura
authors.forename: Shuhei
authors.initials: S
authors.lastname: Sato
authors.forename: Takao
authors.initials: T
authors.lastname: Hiraki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ishii
authors.forename: Hideo
authors.initials: H
authors.lastname: Gobara
authors.forename: Katsuya
authors.initials: K
authors.lastname: Kato
authors.forename: Toshiyoshi
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Miyoshi
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Kaji
authors.forename: Susumu
authors.initials: S
authors.lastname: Kanazawa
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000556:secondary / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D017115:Catheter Ablation; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods / Q000592:standards*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18